Assessment Pembrolizumab (Keytruda): CADTH Reimbursement Suggestion: Indication: In combination with chemotherapy, for your remedy of adult people with locally recurrent unresectable or metastatic triple-destructive breast cancer that have not been given prior chemotherapy for metastatic condition and whose tumours Categorical programmed cell Demis